NCT00411671View on ClinicalTrials.gov

BATTLE Program: Sorafenib in Patients With NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Lung Cancer
Interventions
DRUG

Sorafenib

400 mg By Mouth Twice Daily for 28 Days.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Bayer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER